Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can skipping opioids during hip surgery protect your heart?

NCT ID NCT05446623

Knowledge-focused Sponsor: Centre Hospitalier de Montauban Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two types of general anesthesia for hip replacement surgery: one with opioids and one without. The goal was to see how each affects the heart's pumping ability (cardiac index). 120 adults having planned hip replacement took part. The results help doctors understand if opioid-free anesthesia is safer for the heart.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

120 people

The number who actually took part.

Started

Jan 2021

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible patients for scheduled total hip arthroplasty with general anesthesia. * Patients with an American Society of Anesthesiologists (ASA) score between 1 and 3 * Patient who has received appropriate information and has provided informed consent. * Patient with French social security system. Exclusion Criteria: * Patients eligible to rapid sequence intubation. * Patients with medical contraindication to the use of OFA : allergy to one of the drug used in the protocol, spontaneous bradycardia under 40bpm or atrioventricular block. * Patients with a medical condition that could alter measurement of cardiac index by NICCOMO™: acute pulmonary oedema, severe valvular heart disease, pulmonary hypertension, atrial fibrillation. * Patients who cannot give their informed consent. * Patients pregnant or breastfeeding. * Patients odler than 90 years old or with a weigh superior at 150kg.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip arthropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hip arthropathy Hip disease

Contacts and locations

Locations

  • Edmundo Pereira de Souza Neto

    Montauban, Tarn et Garonne, 82000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.